Somatostatin analogues in the control of neuroendocrine tumours: efficacy and mechanisms.

Somatostatin analogues in the control of neuroendocrine tumours: efficacy and mechanisms.

Neuroendocrine tumours (NETs) represent a heterogeneous family of neoplasms, which may develop from different endocrine glands (such as the pituitary, the parathyroid or the neuroendocrine adrenal glands), endocrine islets (within the thyroid or pancreas) as well as from endocrine cells dispersed be...

Volledige beschrijving

Bibliografische gegevens
Hoofdauteurs:	Grozinsky-Glasberg, S, Shimon, I, Korbonits, M, Grossman, AB
Formaat:	Journal article
Taal:	English
Gepubliceerd in:	2008

Gelijkaardige items

The role of somatostatin analogues in the treatment of neuroendocrine tumours.
door: Grozinsky-Glasberg, S, et al.
Gepubliceerd in: (2008)

Treatment of advanced neuroendocrine tumours with radiolabelled somatostatin analogues.
door: Kaltsas, G, et al.
Gepubliceerd in: (2005)

Imaging neuroendocrine tumours with radiolabelled somatostatin analogues and X-ray computed tomography: a comparative study.
door: King, C, et al.
Gepubliceerd in: (1993)

Are serotonin metabolite levels related to bone mineral density in patients with neuroendocrine tumours?
door: Gupta, P, et al.
Gepubliceerd in: (2014)

Localization of neuroendocrine tumours and insulinomas using radiolabelled somatostatin analogues, 123I-Tyr3-octreotide and 111In-pentatreotide.
door: Ur, E, et al.
Gepubliceerd in: (1993)

The somatostatin analogue octreotide inhibits growth of small intestine neuroendocrine tumour cells.
door: Su-Chen Li, et al.
Gepubliceerd in: (2012-01-01)

Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine tumours, current aspects and new perspectives
door: Baldelli Roberto, et al.
Gepubliceerd in: (2010-03-01)

Somatostatin analogues therapy in gastroenteropancreatic neuroendocrine tumours: current aspects and new perspectives
door: Roberto eBaldelli
Gepubliceerd in: (2014-02-01)

Are serotonin metabolite levels related to bone mineral density in patients with neuroendocrine tumours?
door: Sen Gupta, P, et al.
Gepubliceerd in: (2014)

Transcriptome of GH-producing pituitary neuroendocrine tumours and models are significantly affected by somatostatin analogues
door: Rihards Saksis, et al.
Gepubliceerd in: (2023-02-01)

Efficacy of somatostatine analogues in survival and quality of life of a frail patient with poorly differentiated biliary neuroendocrine tumour
door: Marco Alì, et al.
Gepubliceerd in: (2015-10-01)

Somatostatin analogues stimulate p27 expression and inhibit the MAP kinase pathway in pituitary tumours.
door: Hubina, E, et al.
Gepubliceerd in: (2006)

Comparison of somatostatin receptor expression in patients with neuroendocrine tumours with and without somatostatin analogue treatment imaged with [18F]SiTATE
door: Ralf S. Eschbach, et al.
Gepubliceerd in: (2023-01-01)

Somatostatin Analogue Treatment Increases AIP Protein Expression in Somatotroph Tumours from Patients with Acromegaly and in GH3 Cells in vitro.
door: Chahal, H, et al.
Gepubliceerd in: (2011)

Somatostatin receptor biology in neuroendocrine and pituitary tumours: part 1--molecular pathways.
door: Cakir, M, et al.
Gepubliceerd in: (2010)

Somatostatin receptor biology in neuroendocrine and pituitary tumours: part 2--clinical implications.
door: Cakir, M, et al.
Gepubliceerd in: (2010)

Distinct mechanisms of hypoglycaemia in patients with somatostatin‐secreting neuroendocrine tumours
door: Peter Wiesli, et al.
Gepubliceerd in: (2019-10-01)

Evaluation of the Association between Serotonin and Bone Mineral Density in Patients with Neuroendocrine Tumors
door: Den Gupta, P, et al.
Gepubliceerd in: (2011)

The Global mTOR Inhibitor Torin1 Is More Effective than the mTORC1 Inhibitor, Everolimus, Alone or in Combination with Histone Deacetylase Inhibitors, in Suppressing Neuroendocrine Tumor Cell Proliferation
door: Grozinsky-Glasberg, S, et al.
Gepubliceerd in: (2011)

AIP Mediates the Effects of Somatostatin Analogues in Acromegaly - Evidence from Clinical and Experimental Studies.
door: Chahal, H, et al.
Gepubliceerd in: (2010)

Update on neuroendocrine tumours
door: Grossman, AB
Gepubliceerd in: (2012)

Interaction between somatostatin analogues and targeted therapies in neuroendocrine tumor cells.
door: Sebastian Krug, et al.
Gepubliceerd in: (2019-01-01)

Patient reported symptoms, coping and quality of life during somatostatin analogue treatment for metastatic small- intestinal neuroendocrine tumours
door: Halfdan Sorbye, et al.
Gepubliceerd in: (2020-06-01)

Current treatment strategies for patients with advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs)
door: Inbal Uri, et al.
Gepubliceerd in: (2018-07-01)

Current concepts in the diagnosis and management of type 1 gastric neuroendocrine neoplasms.
door: Kaltsas, G, et al.
Gepubliceerd in: (2014)

Comparison of somatostatin analog and meta-iodobenzylguanidine radionuclides in the diagnosis and localization of advanced neuroendocrine tumors.
door: Kaltsas, G, et al.
Gepubliceerd in: (2001)

Chronic Treatment with Somatostatin Analogues in Recurrent Type 1 Gastric Neuroendocrine Tumors
door: Fernando Sebastian-Valles, et al.
Gepubliceerd in: (2023-03-01)

Initiation of Somatostatin analogues for neuroendocrine tumor patients: a cost-effectiveness analysis
door: Sheila D. Rustgi, et al.
Gepubliceerd in: (2021-05-01)

Treatment with somatostatin analogues and PRRT in metastatic middle ear adenoma with neuroendocrine features
door: Joana Lima Ferreira, et al.
Gepubliceerd in: (2021-05-01)

Patient And Nurse Experience Of Using Somatostatin Analogues To Treat Gastroenteropancreatic Neuroendocrine Tumors: Results Of The Somatostatin Treatment Experience Trial (STREET)
door: Ström T, et al.
Gepubliceerd in: (2019-10-01)

Expression of Somatostatin Receptor 2 in Somatotropinoma Correlated with the Short-Term Efficacy of Somatostatin Analogues
door: Wenjuan Liu, et al.
Gepubliceerd in: (2017-01-01)

Pituitary imaging using a labelled somatostatin analogue in acromegaly.
door: Ur, E, et al.
Gepubliceerd in: (1992)

Radionuclide treatment of neuroendocrine tumours with the novel radiolabelled analogue Y-90-SMT 487
door: Carroll, P, et al.
Gepubliceerd in: (2003)

Growth hormone-releasing peptides (GHRP) and their analogues
door: Korbonits, M, et al.
Gepubliceerd in: (1996)

[Growth hormone-releasing peptides (GHRP) and their analogues]
door: Korbonits, M, et al.
Gepubliceerd in: (1996)

Octreotide and the mTOR inhibitor RAD001 (everolimus) block proliferation and interact with the Akt-mTOR-p70S6K pathway in a neuro-endocrine tumour cell Line.
door: Grozinsky-Glasberg, S, et al.
Gepubliceerd in: (2008)

Paraneoplastic syndromes secondary to neuroendocrine tumours.
door: Kaltsas, G, et al.
Gepubliceerd in: (2010)

Antiangiogenic effects of somatostatin analogues.
door: García de la Torre, N, et al.
Gepubliceerd in: (2002)

Chemokines modulate the tumour microenvironment in pituitary neuroendocrine tumours
door: Pedro Marques, et al.
Gepubliceerd in: (2019-11-01)

Optimal dosage interval for depot somatostatin analogue therapy in acromegaly requires individual titration.
door: Jenkins, P, et al.
Gepubliceerd in: (2000)